Elsevier

Atherosclerosis

Volume 216, Issue 1, May 2011, Pages 244-247
Atherosclerosis

Interleukin-6 in the prediction of primary cardiovascular events in diabetes patients: Results from the ESTHER study

https://doi.org/10.1016/j.atherosclerosis.2011.01.041Get rights and content

Abstract

Objectives

Circulating interleukin-6 (IL-6) is increased in diabetes patients who are in general also at greater cardiovascular risk. Thus, we investigated whether IL-6 is associated with incident primary cardiovascular events and improves risk prediction in diabetes patients.

Methods

Serum IL-6 levels were measured at baseline in 1072 diabetic participants of the ESTHER study. During 5 years of follow-up, 84 experienced a primary cardiovascular event (myocardial infarction, stroke, cardiovascular death). Hazard ratios (HR) and 95% confidence intervals (95% CI), measures of model discrimination and calibration were calculated.

Results

High IL-6 levels were associated with increased event risk (adjusted HR 1.90 [95% CI 1.06–3.40] for top versus bottom tertile; p = 0.011). The addition of IL-6 to models containing Framingham score variables did not substantially improve prediction.

Conclusions

Although serum IL-6 was significantly associated with cardiovascular risk, it did not substantially improve risk prediction above traditional risk factors in a diabetic cohort.

Introduction

Inflammatory processes are major contributors to cardiovascular disease (CVD) [1]. The most frequently investigated immune mediators are C-reactive protein (CRP) and interleukin-6 (IL-6), its main inducer. Despite consistent reports on associations of both immune mediators with cardiovascular risk, a causal relationship appears more likely for chronic elevations of IL-6 than CRP in the circulation [2]. IL-6 may contribute to atherosclerotic plaque development and plaque instability by activation of leukocytes and endothelial cells, induction of other cytokines, chemokines, prothrombotic mediators and matrix metalloproteinases [1], [3].

Recent studies demonstrated associations of increased systemic IL-6 concentrations with incident coronary heart disease, stroke and cardiovascular mortality [4], [5]. However, most studies were conducted in the general population, whereas the relevance of IL-6 for the cardiovascular risk in diabetes patients has received little attention. Type 2 diabetes is a proinflammatory condition [6], and it is still unclear whether a further immune activation contributes to the increased cardiovascular risk in diabetes and whether immune mediators could improve prediction models.

Thus, we examined (i) the association between IL-6 serum concentrations and incidence of primary cardiovascular events and (ii) whether the addition of IL-6 to a model based on established risk factors improves risk prediction in a subsample of 1072 diabetes patients from the ESTHER study.

Section snippets

Methods

This investigation is based on the ESTHER study, an ongoing cohort study including 9953 subjects, aged 50–74 years, recruited by their general practitioners during a routine health check-up between 2000 and 2002 in Saarland, a federal state of Germany [7], [8]. All members of compulsory health insurances in Germany (≈90% of the German population) aged ≥35 years are entitled to have these health-screening examinations focusing on early detection of chronic diseases such as diabetes, CVD and renal

Results

The numbers of participants with incident primary myocardial infarction, stroke and cardiovascular death were 39 (3.6%), 36 (3.4%) and 37 (3.5%), respectively, leading to 84 individuals (7.8%) who reached the composite cardiovascular endpoint. Cases had higher IL-6 levels than controls (median [25th–75th percentile] 3.3 [2.0–7.0] versus 2.6 [1.5–5.1], p = 0.014). Both groups did not differ regarding BMI, systolic blood pressure, lipids, HbA1c, physical inactivity, chronic kidney disease or use of

Discussion

Our main findings are that the strength of association between IL-6 and incident primary cardiovascular events in a cohort of diabetes patients is similar to that found in non-diabetic populations [4], [5], [11] and that adding IL-6 to risk models based on traditional risk factors did not substantially improve prediction. The fact that we could not detect a substantial improvement of cardiovascular risk prediction by IL-6 in our diabetic population (change in AUC <0.01) is in line with previous

Conflict of interest

The authors have no conflicts of interest to disclose.

Acknowledgements

The ESTHER study was funded by the Ministry of Science, Research and Arts of the state Baden-Württemberg (Stuttgart, Germany), the Federal Ministry of Education and Research (Berlin, Germany) and the Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany). Further support for this study was obtained from the Federal Ministry of Health (Berlin, Germany) and the Ministry of Innovation, Science, Research and Technology of the state North-Rhine Westphalia (Düsseldorf,

References (15)

  • Q.L. Zhang et al.

    Epidemiology of chronic kidney disease: results from a population of older adults in Germany

    Prev Med

    (2009)
  • W. Koenig et al.

    Biomarkers of atherosclerotic plaque instability and rupture

    Arterioscler Thromb Vasc Biol

    (2007)
  • P. Elliott et al.

    Genetic loci associated with C-reactive protein levels and risk of coronary heart disease

    JAMA

    (2009)
  • H. Schuett et al.

    How much is too much? Interleukin-6 signalling in atherosclerosis

    Thromb Haemost

    (2009)
  • J. Danesh et al.

    Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review

    PLoS Med

    (2008)
  • W. Whiteley et al.

    Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interlukin-6

    PLoS Med

    (2009)
  • H. Kolb et al.

    An immune origin of type 2 diabetes?

    Diabetologia

    (2005)
There are more references available in the full text version of this article.

Cited by (24)

View all citing articles on Scopus
View full text